IBT Board

 

Andrew Barker (Chairman)

 

He was appointed as a non-executive Director and Chairman of the Company on 16 January 2001. He has been involved in investment management for 39 years, having joined Foreign & Colonial Management Ltd in 1970. He was a director of Foreign & Colonial Ventures Ltd from 1980 to 1998, which is a specialist provider of private equity finance to small and medium sized companies. He was responsible for Foreign & Colonial’s North American investments from 1985 until he retired from Foreign & Colonial in March 2000. His former directorships include The Bankers Investment Trust PLC and Foreign & Colonial Investment Trust PLC. He is Chairman of the British Portfolio Trust plc, JPMorgan Mid Cap Investment Trust plc and Morant Wright Japan Income Trust Ltd. He is also a director of Renaissance US Growth Investment Trust PLC.

 

Véronique Bouchet

 

She was appointed as a non-executive Director of the Company on 1 September 2009. Dr Bouchet is currently Director of Corporate Strategy and Head of Venture Capital Relations at AstraZeneca PLC, having spent the previous twenty years in various clinical development, strategic and business development roles within the healthcare industry, including Zeneca Pharmaceuticals, the Rothschild Bioscience Unit, and latterly AstraZeneca PLC. Her experience encompasses many functions and healthcare industry sectors. She is a qualified medical doctor, holds a BSc in Psychology from University College London and the DRCOG qualification from the Royal College of Obstetricians and Gynaecologists. She has been awarded an MBA from INSEAD and has a Diploma (Distinction) from the Coaching Academy UK.

 

Alan Clifton

 

He was appointed as a non-executive Director of the Company on 21 February 2001. Mr Clifton was previously the Managing Director of Morley Fund Management, the asset management arm of Aviva plc, the UK’s largest insurance group. He is currently Chairman of JPMorgan Fleming Japanese Smaller Companies Investment Trust plc and of Schroder UK Growth Fund plc and a director of several other investment companies.

 

David Clough

 

He was appointed as a non-executive Director of the Company on 25 February 2004. Dr Clough was Director of Research at Roche in the UK between 1986 and 1999. He was responsible for over 300 staff with departments covering chemistry, biology and pre-clinical development.

 

Peter Collacott

 

He was appointed as a non-executive Director of the Company on 25 March 1994. He has more than 40 years experience of the investment management industry having been a managing director of Rothschild Asset Management. Until February 2009, he was a director of Jordan/Zalaznick & Co. Limited, an FSA-regulated investment company, and company secretary of JZ Equity Partners Plc, a listed private equity investment trust, with responsibility for finance and administration. He was appointed chairman of the Audit Committee on 19 April 2004.

 

Alex Hammond-Chambers

 

He was appointed as a non-executive Director of the Company on 21 February 2001. After graduating in Economics at Cambridge University in 1964, Mr Hammond- Chambers joined the investment management firm of Ivory & Sime in Edinburgh, Scotland. Following his formal training period, he became the fund manager of British Assets Trust and Edinburgh American Assets Trust. He became a partner in 1969 and in 1985 Chairman of Ivory & Sime PLC. From 1984 to 1987 he served as a governor of the NASD. In 1991 he retired from Ivory & Sime PLC and has since pursued a second career as a professional non-executive director. He is currently Chairman of Fidelity Special Values PLC, Aurora Investment Trust plc, and Hansa Trust PLC. He is a director of Montanaro European Smaller Companies Trust plc.

 

Ian Macgregor

 

A Chartered Accountant, he was appointed as a nonexecutive Director of the Company on 21 February 2001. He has focused on investment management for more than 20 years. In 1985 he joined The Wellcome Trust, and as Chief Investment Officer he oversaw an increase in the trust’s investment assets from £1 billion to £14 billion, before retiring in 2000. The trust is a major investor in private equity, with a focus on biotechnology both in the UK and the US, and he has served on a number of advisory committees in the private equity/biotechnology area. He also serves on the supervisory board of a number of Common Investment Trusts for Charities.